GLP-1 RAs: Psychiatric, Cognitive, and Quality of Life Effects

This meta-analysis examines the impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RAs), medications used for obesity and diabetes, on the mental health and quality of life of patients. The study analyzed data from 80 randomized clinical trials involving over 107,000 participants with overweight, obesity, or diabetes. Crucially, it found no significant increase in the risk of serious or non-serious psychiatric issues, including depression, associated with GLP1-RA treatment compared to placebo. Furthermore, the analysis suggests positive effects on quality of life, particularly mental and physical health-related quality of life, and improvements in emotional eating and eating restraint. These findings offer reassurance about the psychiatric safety of GLP1-RAs and highlight their potential benefits for emotional well-being in this patient population.